Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement
Open accessAbstract
Peroxisome proliferator-activated receptor-γ (PPARγ) has been reported to be involved in the etiology of pathological features of Alzheimer's disease (AD). Cannabidiol (CBD), a Cannabis derivative devoid of psychomimetic effects, has attracted much attention because of its promising neuroprotective properties in rat AD models, even though the mechanism responsible for such actions remains unknown. This study was aimed at exploring whether CBD effects could be subordinate to its activity at PPARγ, which has been recently indicated as its putative binding site. CBD actions on β-amyloid-induced neurotoxicity in rat AD models, either in presence or absence of PPAR antagonists were investigated. Results showed that the blockade of PPARγ was able to significantly blunt CBD effects on reactive gliosis and subsequently on neuronal damage. Moreover, due to its interaction at PPARγ, CBD was observed to stimulate hippocampal neurogenesis. All these findings report the inescapable role of this receptor in mediating CBD actions, here reported.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CBD decreases neuronal damage induced by β-amyloid protein deposit.
“CBD decreases the neuronal damage induced by β-amyloid protein deposit (105); (114–116)”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [105]
CBD administered intraperitoneally for 15 days prevented neurogenic disruption in a genetic murine model of Alzheimer's Disease through a PPARγ-dependent mechanism.
“CBD (administered intraperitoneally during 15 days) prevented the neurogenic disruption observed in a genetic murine model of Alzheimer's Disease through a peroxisome proliferator-activated receptor γ (PPARγ)-dependent mechanism (105).”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [105]
In vivo, CBD minimizes reactive gliosis.
“In vivo, CBD has shown attenuation of Aβ-induced neuroinflammatory responses by minimizing proinflammatory gene and mediator expression, as well as minimized reactive gliosis [187,190].”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [187]
In vivo, CBD attenuates Aβ-induced neuroinflammatory responses by minimizing proinflammatory gene and mediator expression.
“In vivo, CBD has shown attenuation of Aβ-induced neuroinflammatory responses by minimizing proinflammatory gene and mediator expression, as well as minimized reactive gliosis [187,190].”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [187]
Natural products such as cannabidiol (CBD) and tetrahydrocannabinol (THC) have shown to be effective in vitro and in vivo.
“Consequently, natural products, such as cannabidiol (CBD) and tetrahydrocannabinol (THC), have also shown to be effective in vitro and in vivo [184,185,186,187].”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [187]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Mechanisms underlying inflammation in neurodegeneration
Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580 · see citing works
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C., Lee, V. M. ‐., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,200 · see citing works
Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network
Bookout, A. L., Jeong, Y., Downes, M., Yu, R. T., Evans, R. M., & Mangelsdorf, D. J. (2006) · Cell · doi:10.1016/j.cell.2006.06.049 · Cited by 1,015 · see citing works
Adult neurogenesis: from precursors to network and physiology
Abrous, D. N., Koehl, M., & Le Moal, M. (2005) · Physiological Reviews · doi:10.1152/physrev.00055.2003 · Cited by 971 · see citing works
Cannabidiol and (−)Δ <sup>9</sup> -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850 · see citing works
Integration of metabolism and inflammation by lipid-activated nuclear receptors
Bensinger, S. J., & Tontonoz, P. (2008) · Nature · doi:10.1038/nature07202 · Cited by 813 · see citing works
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors
O’Sullivan, S. E. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707423 · Cited by 509 · see citing works
Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages
Rosa, M. D., Radomski, M. W., Carnuccio, R., & Moncada, S. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91583-e · Cited by 454 · see citing works
Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
Kapadia, R. (2008) · Frontiers in Bioscience · doi:10.2741/2802 · Cited by 433 · see citing works
Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., & Izzo, A. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2003.02327.x · Cited by 361 · see citing works
Self-citationInterleukin-1, neuroinflammation, and Alzheimer's disease
Mrak, R. E. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00287-1 · Cited by 356 · see citing works
Neurogenesis and Alzheimer's disease: At the crossroads
Lazarov, O., & Marr, R. A. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.08.009 · Cited by 326 · see citing works
de la Monte, S. M., & Wands, J. R. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9209 · Cited by 318 · see citing works
Esposito, G., Scuderi, C., Savani, C., Steardo, L., De Filippis, D., Cottone, P., Iuvone, T., Cuomo, V, & Steardo, L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707337 · Cited by 308 · see citing works
Self-citationAstrogliosis in CNS Pathologies: Is There A Role for Microglia?
Zhang, D., Hu, X., Li, Q., O'Callaghan, J. P., & Hong, J. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8098-4 · Cited by 295 · see citing works
Castillo, A., Tolón, M. R., Fernández-Ruiz, J., Romero, J., & Martinez-Orgado, J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.10.023 · Cited by 279 · see citing works
PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease
Landreth, G. E., Jiang, Q., Mandrekar, S., & Heneka, M. T. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.003 · Cited by 277 · see citing works
S100B/RAGE-dependent activation of microglia via NF-κB and AP-1
Bianchi, R., Giambanco, I., & Donato, R. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.017 · Cited by 271 · see citing works
Esposito, G., Filippis, D. D., Carnuccio, R., Izzo, A. A., & Iuvone, T. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0025-1 · Cited by 252 · see citing works
Self-citationFailure of Neuronal Maturation in Alzheimer Disease Dentate Gyrus
Li, B., Yamamori, H., Tatebayashi, Y., Shafit-Zagardo, B., Tanimukai, H., Chen, S., Iqbal, K., & Grundke-Iqbal, I. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318160c5db · Cited by 234 · see citing works
Esposito, G., De Filippis, D., Maiuri, M. C., De Stefano, D., Carnuccio, R., & Iuvone, T. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.01.047 · Cited by 225 · see citing works
Self-citationCannabidiol: A Promising Drug for Neurodegenerative Disorders?
Iuvone, T., Esposito, G., Filippis, D. D., Scuderi, C., & Steardo, L. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00065.x · Cited by 214 · see citing works
Self-citationCannabidiol in medicine: a review of its therapeutic potential in CNS disorders
Scuderi, C., Filippis, D. D., Iuvone, T., Blasio, A., Steardo, A., & Esposito, G. (2008) · Phytotherapy Research · doi:10.1002/ptr.2625 · Cited by 209 · see citing works
Self-citationWolf, S. A., Bick-Sander, A., Fabel, K., Leal-Galicia, P., Tauber, S., Ramirez-Rodriguez, G., Müller, A., Melnik, A., Waltinger, T. P., Ullrich, O., et al. (2010) · Cell Communication and Signaling · doi:10.1186/1478-811x-8-12 · Cited by 208 · see citing works
Mori, T., Koyama, N., Arendash, G. W., Horikoshi‐Sakuraba, Y., Tan, J., & Town, T. (2009) · Glia · doi:10.1002/glia.20924 · Cited by 207 · see citing works
Mechanisms of Cell Signaling and Inflammation in Alzheimers Disease
Ho, G. J., Drego, R., Hakimian, E., & Masliah, E. (2005) · Current Drug Targets - Inflammation & Allergy · doi:10.2174/1568010053586237 · Cited by 199 · see citing works
Landreth, G. E. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00296-2 · Cited by 169 · see citing works
Wada, K., Nakajima, A., Katayama, K., Kudo, C., Shibuya, A., Kubota, N., Terauchi, Y., Tachibana, M., Miyoshi, H., Kamisaki, Y., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513786200 · Cited by 165 · see citing works
Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism
Kersten, S. (2007) · PPAR Research · doi:10.1155/2008/132960 · Cited by 147 · see citing works
PPAR Regulation of Inflammatory Signaling in CNS Diseases
Bright, J. J., Kanakasabai, S., Chearwae, W., & Chakraborty, S. (2008) · PPAR Research · doi:10.1155/2008/658520 · Cited by 131 · see citing works
Magen, I., Avraham, Y., Ackerman, Z., Vorobiev, L., Mechoulam, R., & Berry, E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00589.x · Cited by 121 · see citing works
Feinstein, D. L. (2003) · Diabetes Technology & Therapeutics · doi:10.1089/152091503763816481 · Cited by 115 · see citing works
Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation
Magen, I., Avraham, Y., Ackerman, Z., Vorobiev, L., Mechoulam, R., & Berry, E. M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.021 · Cited by 111 · see citing works
Erythropoietin exerts anti‐apoptotic effects on rat microglial cells in vitro
Vairano, M., Russo, C. D., Pozzoli, G., Battaglia, A., Scambia, G., Tringali, G., Spiriti, M. A. A., Preziosi, P., & Navarra, P. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02125.x · Cited by 107 · see citing works
Esposito, G., Scuderi, C., Lu, J., Savani, C., Filippis, D. D., Iuvone, T., Steardo, L., Jr., Sheen, V. L., & Steardo, L. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00159.x · Cited by 97 · see citing works
Self-citationAvraham, Y., Grigoriadis, N. K., Poutahidis, T., Vorobiev, L., Magen, I., Ilan, Y., Mechoulam, R., & Berry, E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01179.x · Cited by 93 · see citing works
Pregnenolone sulfate enhances neurogenesis and PSA-NCAM in young and aged hippocampus
Mayo, W., Lemaire, V., Malaterre, J., Rodriguez, J. J., Cayre, M., Stewart, M. G., Kharouby, M., Rougon, G. N., Moal, M. L., Piazza, P. V., et al. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.013 · Cited by 90 · see citing works
Secreted β-amyloid precursor protein activates microglia via JNK and p38-MAPK
Bodles, A. M., & Barger, S. W. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.022 · Cited by 82 · see citing works
COX-2 and Alzheimer’s disease: potential roles in inflammation and neurodegeneration
O’Banion, M. K. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.10.1521 · Cited by 58 · see citing works
PPARγ stimulation promotes neurite outgrowth in SH-SY5Y human neuroblastoma cells
Miglio, G., Rattazzi, L., Rosa, A. C., & Fantozzi, R. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.03.014 · Cited by 42 · see citing works
Can novel therapeutics halt the amyloid cascade?
Prins, N. D., Visser, P. J., & Scheltens, P. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt28 · Cited by 20 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Molecular Targets of Cannabidiol in Neurological Disorders
Bih, C. I., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M. L., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 582 · see citing works
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
Burstein, S. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.059 · Cited by 573 · see citing works
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475 · see citing works
Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 484 · see citing works
An update on PPAR activation by cannabinoids
O’Sullivan, S. E. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13497 · Cited by 469 · see citing works
Molecular Targets of the Phytocannabinoids: A Complex Picture
Morales, P., Hurst, D. P., & Reggio, P. H. (2017) · Fortschritte der Chemie Organischer Naturstoffe/Fortschritte der Chemie organischer Naturstoffe/Progress in the chemistry of organic natural products · doi:10.1007/978-3-319-45541-9_4 · Cited by 488 · see citing works
Cannabidiol, neuroprotection and neuropsychiatric disorders
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446 · see citing works
Pellati, F., Borgonetti, V., Brighenti, V., Biagi, M., Benvenuti, S., & Corsi, L. (2018) · BioMed Research International · doi:10.1155/2018/1691428 · Cited by 375 · see citing works
Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation
Villapol, S. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0554-5 · Cited by 372 · see citing works
Fernández‐Ruíz, J., Sagredo, O., Pazos, M. R., García, C., Pertwee, R. G., Mechoulam, R., & Martínez-Orgado, J. A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04341.x · Cited by 356 · see citing works
Campos, A. C., Ortega, Z., Palazuelos, J., Fogaça, M. V., Aguiar, D. C., Díaz-Alonso, J., Ortega-Gutiérrez, S., Vázquez-Villa, H., Moreira, F. A., Guzmán, M., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001502 · Cited by 313 · see citing works
Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308 · see citing works
Immune Responses Regulated by Cannabidiol
Nichols, J. M., & Kaplan, B. L. F. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0073 · Cited by 297 · see citing works
Linge, R., Jiménez-Sánchez, L., Campa, L., Pilar-Cuéllar, F., Vidal, R., Pazos, Á., Adell, A., & Díaz, Á. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.017 · Cited by 285 · see citing works
Neuroinflammation in Alzheimer&rsquo;s disease
Zhang, F., & Jiang, L. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75546 · Cited by 276 · see citing works
Jadoon, K. A., Ratcliffe, S. H., Barrett, D. A., Thomas, E. L., Stott, C. G., Bell, J. D., O’Sullivan, S. E., & Tan, G. D. (2016) · Diabetes Care · doi:10.2337/dc16-0650 · Cited by 262 · see citing works
Diversity of molecular targets and signaling pathways for CBD
de Almeida, D. L., & Devi, L. A. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.682 · Cited by 264 · see citing works
Baron, E. P. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13345 · Cited by 256 · see citing works
Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
Aso, E., & Ferrer, I. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00037 · Cited by 244 · see citing works
In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease
Watt, G., & Karl, T. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00020 · Cited by 227 · see citing works
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx073 · Cited by 226 · see citing works
Fogaça, M. V., Campos, A. C., Coelho, L. D., Duman, R. S., & Guimarães, F. S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.03.001 · Cited by 208 · see citing works
Review of the neurological benefits of phytocannabinoids
Maroon, J. C., & Bost, J. (2018) · Surgical Neurology International · doi:10.4103/sni.sni_45_18 · Cited by 208 · see citing works
Sales, A. J., Fogaça, M. V., Sartim, A. G., Pereira, V. S., Wegener, G., Guimarães, F. S., & Joca, S. R. L. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1143-4 · Cited by 199 · see citing works
Review of Eukaryote Cellular Membrane Lipid Composition, with Special Attention to the Fatty Acids
Ali, O., & Szabó, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115693 · Cited by 206 · see citing works
In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa
Zagzoog, A., Mohamed, K. A., Kim, H. J. J., Kim, E. D., Frank, C., Black, T., Jadhav, P. D., Holbrook, L. A., & Laprairie, R. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-77175-y · Cited by 180 · see citing works
An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol
Morales, P., Reggio, P. H., & Jagerovic, N. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00422 · Cited by 181 · see citing works
Campos, A. C., Fogaça, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., Sonego, A. B., Rodrigues, N. S., Galve-Roperh, I., & Guimarães, F. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00269 · Cited by 175 · see citing works
Cheng, D., Low, J. K., Logge, W., Garner, B., & Karl, T. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3478-5 · Cited by 172 · see citing works
The Role of Glutamate Receptors in Epilepsy
Chen, T., Huang, T., Lai, M., & Huang, C. (2023) · Biomedicines · doi:10.3390/biomedicines11030783 · Cited by 176 · see citing works
Pereira, M. D. S., Guimarães, F. S., Del‐Bel, E., Raisman‐Vozari, R., & Michel, P. P. (2019) · Glia · doi:10.1002/glia.23738 · Cited by 169 · see citing works
A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis
Granja, A. G., Carrillo-Salinas, F. J., Pagani, A., Gómez‐Cañas, M., Negri, R., Navarrete, C. M., Mecha, M., Mestre, L., Fiebich, B. L., Cantarero, I., et al. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9399-3 · Cited by 165 · see citing works
Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
Peres, F. F., Lima, A. C., Hallak, J. E. C., Crippa, J. A. S., Silva, R. H., & Abílio, V. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00482 · Cited by 160 · see citing works
González‐Cuevas, G., Martin‐Fardon, R., Kerr, T. M., Stouffer, D. G., Parsons, L. H., Hammell, D. C., Banks, S. L., Stinchcomb, A. L., & Weiss, F. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0050-8 · Cited by 157 · see citing works
Hippocampal harms, protection and recovery following regular cannabis use
Yücel, M., Lorenzetti, V., Suo, C., Zalesky, A., Fornito, A., Takagi, M., Lubman, D. I., & Solowij, N. (2016) · Translational Psychiatry · doi:10.1038/tp.2015.201 · Cited by 153 · see citing works
Fogaça, M. V., Reis, F. M. C. V., Campos, A. C., & Guimarães, F. S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.012 · Cited by 153 · see citing works
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia
Osborne, A. L., Solowij, N., & Weston–Green, K. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.012 · Cited by 150 · see citing works
The Polypharmacological Effects of Cannabidiol
Castillo-Arellano, J. I., Canseco-Alba, A., Cutler, S. J., & León, F. (2023) · Molecules · doi:10.3390/molecules28073271 · Cited by 163 · see citing works
Molecular and Cellular Mechanisms of Action of Cannabidiol
Naya, N. M., Kelly, J., Corna, G., Golino, M., Abbate, A., & Toldo, S. A. (2023) · Molecules · doi:10.3390/molecules28165980 · Cited by 158 · see citing works
Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection
More, S. V., & Choi, D. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0012-0 · Cited by 145 · see citing works
Cassano, T., Villani, R., Pace, L., Carbone, A., Bukke, V. N., Orkisz, S., Avolio, C., & Serviddio, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00124 · Cited by 148 · see citing works
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol
Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135 · see citing works
Campos, A. C., Ferreira, F. R., & Guimarães, F. S. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.012 · Cited by 139 · see citing works
Fernández‐Ruíz, J., Romero, J., & Ramos, J. A. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_8 · Cited by 132 · see citing works
Cannabis Therapeutics and the Future of Neurology
Russo, E. B. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00051 · Cited by 132 · see citing works
Shadfar, S., Hwang, C. J., Lim, M., Choi, D., & Hong, J. T. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0648-x · Cited by 130 · see citing works
Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595635 · Cited by 129 · see citing works
Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment
Premoli, M., Aria, F., Bonini, S. A., Maccarinelli, G., Gianoncelli, A., Pina, S. D., Tambaro, S., Memo, M., & Mastinu, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.053 · Cited by 125 · see citing works
Cannabinoids Decrease the Th17 Inflammatory Autoimmune Phenotype
Kozela, E., Juknat, A., Kaushansky, N., Rimmerman, N., Ben‐Nun, A., & Vogel, Z. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9493-1 · Cited by 123 · see citing works
Is the cardiovascular system a therapeutic target for cannabidiol?
Stanley, C. P., Hind, W. H., & O’Sullivan, S. E. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04351.x · Cited by 121 · see citing works
Grifoni, L., Vanti, G., Donato, R., Sacco, C., & Bilia, A. R. (2022) · Molecules · doi:10.3390/molecules27186070 · Cited by 118 · see citing works
Janefjord, E., Mååg, J. L. V., Harvey, B. S., & Smid, S. D. (2014) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-013-9984-x · Cited by 118 · see citing works
Lötsch, J., Weyer-Menkhoff, I., & Tegeder, I. (2017) · European Journal of Pain · doi:10.1002/ejp.1148 · Cited by 118 · see citing works
Juknat, A., Pietr, M., Kozela, E., Rimmerman, N., Levy, R., Gao, F., Coppola, G., Geschwind, D. H., & Vogel, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061462 · Cited by 117 · see citing works
Cannabidiol as a potential treatment for psychosis
Davies, C., & Bhattacharyya, S. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319881916 · Cited by 113 · see citing works
Aymerich, M. S., Aso, E., Abellanas, M. A., Tolón, R. M., Ramos, J. A., Ferrer, I., Romero, J., & Fernández‐Ruíz, J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.08.016 · Cited by 110 · see citing works
Terpenoids, Cannabimimetic Ligands, beyond the Cannabis Plant
Gonçalves, E. C. D., Baldasso, G. M., Bicca, M. A., Paes, R. S., Capasso, R., & Dutra, R. C. (2020) · Molecules · doi:10.3390/molecules25071567 · Cited by 111 · see citing works
Cannabidiol for neurodegenerative disorders: A comprehensive review
Bhunia, S., Kolishetti, N., Yndart, A., Vashist, A., & Nair, M. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989717 · Cited by 115 · see citing works
Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
Libro, R., Giacoppo, S., Soundara Rajan, T., Bramanti, P., & Mazzon, E. (2016) · Molecules · doi:10.3390/molecules21040518 · Cited by 107 · see citing works
Bedse, G., Romano, A., Lavecchia, A. M., Cassano, T., & Gaetani, S. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141635 · Cited by 104 · see citing works
Endocannabinoids: A unique opportunity to develop multitarget analgesics
Maione, S., Costa, B., & Marzo, V. D. (2013) · Pain · doi:10.1016/j.pain.2013.03.023 · Cited by 102 · see citing works
Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview
Esposito, G., Filippis, D. D., Cirillo, C., Iuvone, T., Capoccia, E., Scuderi, C., Steardo, A., Cuomo, R., & Steardo, L. (2012) · Phytotherapy Research · doi:10.1002/ptr.4781 · Cited by 102 · see citing works
Self-citationScuderi, C., Stecca, C., Valenza, M., Ratano, P., Bronzuoli, M. R., Bartoli, S., Steardo, L., Pompili, E., Fumagalli, L., Campolongo, P., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.376 · Cited by 100 · see citing works
Self-citationCannabidiol Therapy for Refractory Epilepsy and Seizure Disorders
Golub, V. M., & Reddy, D. S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-57369-0_7 · Cited by 98 · see citing works
Schiavon, A. P., Soares, L. M., Bonato, J. M., Milani, H., Guimarães, F. S., & de Oliveira, R. M. W. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9457-0 · Cited by 96 · see citing works
Silote, G. P., Sartim, A. G., Sales, A. J., Eskelund, A., Guimarães, F. S., Wegener, G., & Joca, S. R. L. (2019) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2019.04.006 · Cited by 93 · see citing works
Campos, A. C., Brant, F., de Miranda, A. S., Machado, F. S., & Teixeira, A. L. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.12.051 · Cited by 93 · see citing works
Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer’s Disease
Schubert, D. A., Kepchia, D., Liang, Z., Dargusch, R., Goldberg, J., & Maher, P. A. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1637-8 · Cited by 92 · see citing works
Kip, E., & Parr‐Brownlie, L. C. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1092537 · Cited by 96 · see citing works
Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease
Silvestro, S., Schepici, G., Bramanti, P., & Mazzon, E. (2020) · Molecules · doi:10.3390/molecules25215186 · Cited by 90 · see citing works
D’Aniello, E., Fellous, T. G., Iannotti, F. A., Gentile, A., Allarà, M., Balestrieri, F., Gray, R., Amodeo, P., Vitale, R. M., & Marzo, V. D. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.01.002 · Cited by 87 · see citing works
Hegde, V. L., Singh, U. P., Nagarkatti, P. S., & Nagarkatti, M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401844 · Cited by 87 · see citing works
Cannabidiol modulation of oxidative stress and signalling
Pereira, S. R., Hackett, B., O’Driscoll, D. N., Sun, M. C., & Downer, E. J. (2021) · Neuronal Signaling · doi:10.1042/ns20200080 · Cited by 90 · see citing works
Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol
Bielawiec, P., Harasim‐Symbor, E., & Chabowski, A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00114 · Cited by 82 · see citing works
Cannabidiol induces autophagy via ERK1/2 activation in neural cells
Vrechi, T. A. D. M., Leão, A. H. F. F., Morais, I. B. M., Abílio, V. C., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. S., Bincoletto, C., Ureshino, R. P., Smaili, S. S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84879-2 · Cited by 85 · see citing works
Role of Calcium Modulation in the Pathophysiology and Treatment of Alzheimer’s Disease
Baracaldo-Santamaría, D., Avendaño-Lopez, S. S., Ariza-Salamanca, D. F., Rodríguez-Giraldo, M., Calderón‐Ospina, C., González-Reyes, R. E., & Nava-Mesa, M. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109067 · Cited by 85 · see citing works
Reddy, D. S. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114237 · Cited by 100 · see citing works
The influence of cannabinoids on generic traits of neurodegeneration
Fagan, S. G., & Campbell, V. A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12492 · Cited by 78 · see citing works
Díaz-Alonso, J., Paraíso‐Luna, J., Navarrete, C. M., del Río, C., Cantarero, I., Palomares, B., Aguareles, J., Fernández‐Ruíz, J., Bellido, M. L., Pollastro, F., et al. (2016) · Scientific Reports · doi:10.1038/srep29789 · Cited by 78 · see citing works
The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer’s disease
Karl, T., Garner, B., & Cheng, D. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000247 · Cited by 78 · see citing works
Singh, S., Nagalakshmi, D., Sharma, K. K., & Ravichandiran, V. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e06216 · Cited by 77 · see citing works
Barichello, T., Ceretta, R. A., Generoso, J. S., Moreira, A. P., Simões, L. R., Comim, C. M., Quevedo, J., Vilela, M. C., Zuardi, A. W., Crippa, J. A., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.053 · Cited by 76 · see citing works
Sonego, A. B., Prado, D. D. S., do Vale, G. T., Sepulveda-Diaz, J. E., Cunha, T. M., Tirapelli, C. R., Bel, E. A. D., Raisman‐Vozari, R., & Guimarães, F. S. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.09.014 · Cited by 76 · see citing works
Espejo‐Porras, F., Fernández‐Ruíz, J., Pertwee, R. G., Mechoulam, R., & García, C. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.024 · Cited by 75 · see citing works
Mayer, C., Riera‐Ponsati, L., Kauppinen, S., Klitgaard, H., Erler, J. T., & Hansen, S. N. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1437939 · Cited by 75 · see citing works
Filipiuc, L.-E., Ababei, D. C., Alexa‐Stratulat, T., Pricope, C. V., Bild, V., Ştefănescu, R., Stanciu, G. D., & Tamba, B.-I. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111823 · Cited by 72 · see citing works
Vitale, R. M., Iannotti, F. A., & Amodeo, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094876 · Cited by 74 · see citing works
Flack, N., Colwell, M., Drown, C., & Faulk, C. D. (2021) · Clinical Epigenetics · doi:10.1186/s13148-020-00993-4 · Cited by 72 · see citing works
Cannabidiol Reverses Deficits in Hippocampal LTP in a Model of Alzheimer’s Disease
Hughes, B., & Herron, C. E. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2513-z · Cited by 72 · see citing works
Pharmacological effects of cannabidiol by transient receptor potential channels
Etemad, L., Karimi, G., Alavi, M. S., & Roohbakhsh, A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120582 · Cited by 73 · see citing works
Feliú, A., Moreno‐Martet, M., Mecha, M., Carrillo-Salinas, F. J., de Lago, E., Fernández‐Ruíz, J., & Guaza, C. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13159 · Cited by 70 · see citing works
Role of PPAR γ in the Differentiation and Function of Neurons
Quintanilla, R. A., Utreras, E., & Cabezas-Opazo, F. (2014) · PPAR Research · doi:10.1155/2014/768594 · Cited by 69 · see citing works
Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid
Kozela, E., Juknat, A., & Vogel, Z. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081669 · Cited by 70 · see citing works
Lazarini-Lopes, W., Silva, R. A. D. V.-D., da Silva-Júnior, R. M. P., Leite, J. P., & Garcia‐Cairasco, N. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.01.014 · Cited by 69 · see citing works
Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study
Leehey, M. A., Liu, Y., Hart, F., Epstein, C. H., Cook, M., Sillau, S., Klawitter, J., Newman, H., Sempio, C., Forman, L., et al. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2019.0068 · Cited by 69 · see citing works
Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer’s Disease
Talarico, G., Trebbastoni, A., Bruno, G., & de Lena, C. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180702144644 · Cited by 69 · see citing works
Florensa-Zanuy, E., Garro-Martínez, E., Adell, A., Castro, E., Díaz, Á., Pazos, Á., MacDowell, K. S., Martín‐Hernández, D., & Pilar-Cuéllar, F. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114433 · Cited by 68 · see citing works
Mannan, A., Garg, N., Singh, T. G., & Kang, H. K. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03402-1 · Cited by 68 · see citing works
Watt, G., Shang, K., Zieba, J., Olaya, J. C., Li, H., Garner, B., & Karl, T. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191242 · Cited by 68 · see citing works
Ożarowski, M., Karpiński, T. M. M., Zielińska, A., Souto, E. B., & Wielgus, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094294 · Cited by 69 · see citing works
- Authors
- Esposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De Filippis, D., Cipriano, M., Carratù, M. R., Iuvone, T., & Steardo, L.
- Affiliations
- Sapienza University of Rome (IT)
- University of Bari Aldo Moro (IT)
- University of Naples Federico II (IT)
- Corresponding author
- Steardo, Luca
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-12-05
- Volume
- 6
- Issue
- 12
- Pages
- e28668
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3230631
- OpenAlex
- W2107076749
- Cited by
- 410
- References
- 41
- Citations by year
- 2026: 23 · 2025: 24 · 2024: 53 · 2023: 41 · 2022: 49 · 2021: 48 · 2020: 45 · 2019: 22 · 2018: 18 · 2017: 26 · 2016: 16 · 2015: 13 · 2014: 8 · 2013: 13 · 2012: 10
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- cannabidiol, PPARγ, Alzheimer's disease, amyloid-beta, neuroinflammation, hippocampal neurogenesis, reactive gliosis, neuroprotection, PPARγ antagonist, neurotoxicity
- MeSH terms
- Animals, Astrocytes, Binding Sites, Brain, Cannabidiol, Hippocampus, Inflammation, Male, Neurons, Nitric Oxide, Protein Binding, Time Factors, Amyloid beta-Peptides, Rats, Sprague-Dawley, Protein Structure, Tertiary, PPAR gamma, Rats, Neurogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
